JCI table of contents: April 22, 2008(hone: 33-1-46-54-94-69; Fax: 33-1-46-54-...)

View the PDF of this article at: https://www.the-jci.org/article.php?id=33037

ACCOMPANYING COMMENTARY
TITLE: Is Nef the elusive cause of HIV-associated hematopoietic dysfunction?

AUTHOR CONTACT:
Frank Kirchhoff
University of Ulm, Ulm, Germany.
Phone: 49-731-50065109; Fax: 49-731-50065131; E-mail: frank.kirchhoff@uniklinik-ulm.de.

Guido Silvestri
University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Phone: (215) 573-5363; Fax: (215) 573-5366; E-mail: gsilvest@mail.med.upenn.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=35487

Unlike normal cells, which have three cyclin D proteins that can each cover for the others, the cells of many types of cancer, especially blood cancers such as multiple myeloma, express only one cyclin D protein. This has led to the suggestion that targeting individual cyclin D proteins might provide a good approach to treating individuals with cancers characterized by a reliance on just one cyclin D protein. Evidence to support this idea has now been generated in preclinical models by Keith Stewart and colleagues, at the Mayo Clinic in Scottsdale, Arizona.

In the study, a large number of chemicals were screened for their ability to inhibit the expression of the CCND2 gene, which is the gene that carries the information for making the cyclin D2 protein. During the screen, a chemical from plants known as kinetin riboside was shown to inhibit expression of both
'/>"/>